Payment overview · 2025
General Payments
$367.31
17 reported records · 13 companies
Healthcare provider profile · identity verified
Eric A Huerter, M.D.
Allopathic & Osteopathic Physicians|General Practice · LAWRENCE, KS · NPI 1225133812
Verified facts
What the public records show
CMS Open Payments records show Eric A Huerter, M.D. received $367.31 in general payments during 2025 across 17 reported records.
Amgen Inc. accounted for 16.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 431 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $61.22 | 16.7% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $40.27 | 11.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $38.94 | 10.6% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $32.75 | 8.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.47 | 8.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $26.80 | 7.3% | 1 | 2025 |
| SPR Therapeutics, Inc | Unresolved — no canonical attribution shown | $25.23 | 6.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.74 | 6.2% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.57 | 6.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.89 | 5.7% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $15.88 | 4.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.00 | 4.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.55 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $367.31 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $45.15 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $40.27 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $38.94 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $32.75 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $31.47 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $26.80 | 1 | 2025 |
Source payment records
|
|||||
| SPRINT PNS System Normalized: sprint pns system |
Device | SPR Therapeutics, Inc | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $23.38 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.74 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $22.57 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 431 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 135 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
135 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
135 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
431 | 48 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
33 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1120 | 143 |
| Atorvastatin Calcium | Atorvastatin Calcium | 872 | 144 |
| Losartan Potassium | Losartan Potassium | 606 | 109 |
| Omeprazole | Omeprazole | 552 | 97 |
| Potassium Chloride | Potassium Chloride | 550 | 78 |
| Furosemide | Furosemide | 446 | 82 |
| Eliquis | Apixaban | 431 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 422 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 361 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 338 | 53 |
| Gabapentin | Gabapentin | 328 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 328 | 59 |
| Citalopram Hbr | Citalopram Hydrobromide | 326 | 46 |
| Simvastatin | Simvastatin | 311 | 42 |
| Sertraline Hcl | Sertraline Hcl | 308 | 52 |
| Trazodone Hcl | Trazodone Hcl | 298 | 58 |
| Lisinopril | Lisinopril | 281 | 42 |
| Carvedilol | Carvedilol | 248 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 236 | 33 |
| Donepezil Hcl | Donepezil Hcl | 236 | 35 |
| Meloxicam | Meloxicam | 231 | 63 |
| Metformin Hcl | Metformin Hcl | 196 | 31 |
| Allopurinol | Allopurinol | 181 | 29 |
| Famotidine | Famotidine | 180 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 175 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 174 | 35 |
| Mirtazapine | Mirtazapine | 173 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 169 | 29 |
| Prednisone | Prednisone | 167 | 72 |
| Memantine Hcl | Memantine Hcl | 160 | 23 |
| Tramadol Hcl | Tramadol Hcl | 160 | 51 |
| Vascepa | Icosapent Ethyl | 153 | 12 |
| Levetiracetam | Levetiracetam | 150 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 147 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 143 | 41 |
| Xarelto | Rivaroxaban | 139 | 17 |
| Jardiance | Empagliflozin | 135 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 129 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 123 | 11 |
| Ezetimibe | Ezetimibe | 122 | 25 |
| Montelukast Sodium | Montelukast Sodium | 117 | 19 |
| Spironolactone | Spironolactone | 116 | 15 |
| Baclofen | Baclofen | 112 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 110 | 14 |
| Lorazepam | Lorazepam | 110 | 36 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 109 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 104 | 15 |
| Clonazepam | Clonazepam | 104 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 102 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 23 |
| Risperidone | Risperidone | 93 | 19 |
| Cephalexin | Cephalexin | 89 | 65 |
| Januvia | Sitagliptin Phosphate | 84 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 79 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 78 | 29 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 78 | 12 |
| Estradiol | Estradiol | 76 | 15 |
| Azithromycin | Azithromycin | 75 | 65 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 14 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 74 | 74 |
| Cefdinir | Cefdinir | 71 | 54 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 14 |
| Pregabalin | Pregabalin | 68 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 67 | 12 |
| Alendronate Sodium | Alendronate Sodium | 66 | 13 |
| Bupropion Xl | Bupropion Hcl | 64 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | suppressed |
| Ozempic | Semaglutide | 57 | suppressed |
| Alprazolam | Alprazolam | 55 | 20 |
| Colestipol Hcl | Colestipol Hcl | 55 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 13 |
| Divalproex Sodium | Divalproex Sodium | 54 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 53 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 39 |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 38 |
| Methenamine Hippurate | Methenamine Hippurate | 51 | suppressed |
| Nystatin | Nystatin | 50 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Acyclovir | Acyclovir | 48 | suppressed |
| Atenolol | Atenolol | 48 | suppressed |
| Hydrocortisone | Hydrocortisone | 48 | suppressed |
| Linzess | Linaclotide | 48 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 48 | suppressed |
| Lactulose | Lactulose | 47 | suppressed |
| Nystop | Nystatin | 45 | 22 |
| Clonidine Hcl | Clonidine Hcl | 44 | suppressed |
| Torsemide | Torsemide | 44 | suppressed |
| Aripiprazole | Aripiprazole | 43 | suppressed |
| Lovastatin | Lovastatin | 43 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 41 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 41 | 40 |
| Finasteride | Finasteride | 40 | suppressed |
| Fluconazole | Fluconazole | 40 | 28 |
| Glimepiride | Glimepiride | 40 | suppressed |
| Latanoprost | Latanoprost | 40 | 12 |
| Chlorthalidone | Chlorthalidone | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 17 |
| Celecoxib | Celecoxib | 38 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 29 |
| Glycopyrrolate | Glycopyrrolate | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 35 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Valsartan | Valsartan | 34 | suppressed |
| Loperamide | Loperamide Hcl | 33 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 33 |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Bumetanide | Bumetanide | 31 | suppressed |
| Colchicine | Colchicine | 31 | 12 |
| Creon | Lipase/Protease/Amylase | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 13 |
| Haloperidol | Haloperidol | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 18 |
| Oxcarbazepine | Oxcarbazepine | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 14 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 27 | suppressed |
| Water | Water For Irrigation,sterile | 27 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | suppressed |
| Xtampza Er | Oxycodone Myristate | 26 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 17 |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Diazepam | Diazepam | 24 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Trospium Chloride | Trospium Chloride | 24 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Minoxidil | Minoxidil | 22 | suppressed |
| Scopolamine | Scopolamine | 22 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 21 | 18 |
| Armour Thyroid | Thyroid,pork | 21 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 17 |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Norethindrone | Norethindrone | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Famciclovir | Famciclovir | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Pimtrea | Desog-E.Estradiol/E.Estradiol | 17 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 17 | suppressed |
| Calcium Acetate | Calcium Acetate | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 15 | suppressed |
| Tarina Fe 1-20 Eq | Norethindrone-E.Estradiol-Iron | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Eplerenone | Eplerenone | 13 | suppressed |
| Ethosuximide | Ethosuximide | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Juleber | Desogestrel-Ethinyl Estradiol | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Rytary | Carbidopa/Levodopa | 13 | suppressed |
| Bicalutamide | Bicalutamide | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Felbamate | Felbamate | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Sulfacetamide Sodium | Sulfacetamide Sodium | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $367.31 · 17 records | Amgen Inc. | ACCRUFER, Dexcom G6 Transmitter, ELIQUIS, EVENITY, IBSRELA, JARDIANCE, LEQVIO, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, REPATHA, REXULTI, SPRINT PNS System, ZENPEP, ZEPBOUND, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error